Active	Status	Sponsor type	Region	Phase	Filter
23 Active 9 Inactive 32 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

23 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kierkus, Jaroslaw
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease	Recruiting	4	304	Europe, Canada, US, RoW	Vedolizumab	Alimentiv Inc., Takeda	Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn	01/27	09/28
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis	Active, not recruiting	4	672	Europe, Canada, US, RoW	Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C	Alimentiv Inc., Takeda Development Center Americas, Inc.	Colitis, Ulcerative	03/26	03/26
Vedolizumab-3041, NCT06443502: A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis	Recruiting	3	30	Europe, RoW	Vedolizumab, Entyvio, MLN0002, Kynteles, Concomitant Antibiotic Therapy	Takeda	Pouchitis	12/29	12/29
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)	Recruiting	3	120	Europe, Canada, Japan, US, RoW	Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002	Takeda, Takeda Development Center Americas, Inc.	Crohn's Disease (CD)	11/24	11/24
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis	Recruiting	3	1063	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis	07/26	12/27
NCT04701411 / 2020-003193-48: A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease	Recruiting	3	20	Europe, Japan, RoW	Darvadstrocel, Cx601	Takeda, Takeda Development Center Americas, Inc.	Crohn's Disease, Complex Perianal Fistula	06/25	12/25
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)	Active, not recruiting	3	121	Europe, Canada, Japan, US, RoW	Vedolizumab, MLN0002, ENTYVIO, KYNTELES	Takeda, Takeda Development Center Americas, Inc.	Colitis, Ulcerative	08/25	08/25
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease	Recruiting	3	90	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company, Eli Lilly and Company	Crohn's Disease	07/27	10/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease	Recruiting	3	150	Europe, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company, Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease	07/30	07/30
NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)	Recruiting	3	240	Europe, Canada, Japan, US, RoW	Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention	Takeda, Takeda Development Center Americas, Inc.	Ulcerative Colitis, Crohn's Disease	08/31	08/31
NCT04710524 / 2020-005187-63: FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis	Recruiting	2a	60	Europe	Placebo, FM101 150 mg BID, FM101 300 mg BID	Future Medicine	Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis	05/23	08/23
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease	Recruiting	2	268	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Crohn's Disease	09/26	07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis	Recruiting	2	207	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Ulcerative Colitis	09/26	08/27
NCT02616302 / 2014-004506-15: A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old	Recruiting	2	70	Europe, Canada, US, RoW	Dexlansoprazole, Dexilant	Takeda	Gastroesophageal Reflux Disease (GERD)	10/27	10/27
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet	Completed	2	153	Europe, Canada, US	TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar	Takeda	Celiac Disease	11/24	11/24
NCT02615184 / 2014-004507-73: A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old	Recruiting	2	76	Europe, Canada, US, RoW	Dexlansoprazole, Dexilant	Takeda	Erosive Esophagitis	10/27	10/27
PIBD-NUTS, NCT06723418: Development and Validation of a New Paediatric Inflammatory Bowel Disease NUTrition Risk Score	Recruiting	N/A	2000	Europe, RoW	Malnutriton Screening Tool (PYMS)	University of Glasgow	Inflammatory Bowel Diseases (IBD), Crohns Disease, Ulcerative Colitis (UC)	12/26	12/26
Rokicki, Dariusz
NCT05933200 / 2022-001539-10: A Study to Determine the Effect of Triheptanoin Compared With Even-chain, MCT on MCEs in Pediatric Patients With LC-FAOD	Active, not recruiting	3	60	Europe, Japan, RoW	Triheptanoin, UX007, Dojolvi, MCT Oil, Medium-chain Triglyceride	Ultragenyx Pharmaceutical Inc, Ultragenyx Pharmaceutical Inc.	Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)	09/26	09/26
EMPAtia, NCT04930627: Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia	Not yet recruiting	2	20	Europe	Empagliflozin, Jardiance	Children's Memorial Health Institute, Poland, Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw	Glucose 6 Phosphatase Deficiency	06/24	03/25
Kaczor, Magdalena
EMPAtia, NCT04930627: Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia	Not yet recruiting	2	20	Europe	Empagliflozin, Jardiance	Children's Memorial Health Institute, Poland, Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw	Glucose 6 Phosphatase Deficiency	06/24	03/25
Socha, Piotrem
NCT05239858: International Wilson's Disease Patient Registry (iWilson Registry)	Recruiting	N/A	500	Europe, RoW		Orphalan, Ergomed	Wilson's Disease	12/27	12/27